MRK - Merck & Co., Inc.
| Previous Close | 74.69 |
| Open | 75.22 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 3100 |
| Day's Range | 74.01 - 75.27 |
| 52 Week Range | 52.83 - 75.99 |
| Volume | 15,827,652 |
| Avg. Volume | 10,128,032 |
| Market Cap | 194.014B |
| Beta (3Y Monthly) | 0.60 |
| PE Ratio (TTM) | 153.84 |
| EPS (TTM) | 0.49 |
| Earnings Date | Jan 31, 2019 - Feb 4, 2019 |
| Forward Dividend & Yield | 2.20 (2.94%) |
| Ex-Dividend Date | 2018-12-14 |
| 1y Target Est | 79.12 |
- GuruFocus.com•8 hours ago
Daniel Loeb Purchases 7 Stocks in 3rd Quarter
Third Point's buying slows as it seeks 'compounders of value'
- Business Wire•9 hours ago
Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
Merck (MRK), known as MSD outside the United States and Canada, today announced that it has started the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated), the company’s investigational vaccine for Ebola Zaire disease. This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by the company in July 2016.
- Zacks•12 hours ago
Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates
Bayer (BAYRY) surpasses earnings and sales estimates in the third quarter of 2018 and reiterates outlook for 2018.
Markit•18 hours agoSee what the IHS Markit Score report has to say about Merck & Co Inc.
Merck & Co Inc NYSE:MRK
- InvestorPlace•yesterday
5 Stocks to Sell After the Midterm Election
After Democrats obtained a narrow majority in the House of Representatives in the midterm elections, both House Democrats and President Trump will likely be looking to make at least some deals. To retain their majority, House Democrats will have to convince moderate voters in the swing districts that Democrats narrowly won that they are moderate and can be productive. For his part, President Trump will likely have to convince at least some moderate voters, i.e., centrist suburban women and independents that he can make deals that will make the country and their lives better.
- Benzinga•yesterday
October's biggest Losers And Most Surprising Winners
Using trading platform Finscreener’s chartboard tools, we can take a look at the top mega-cap gainers in the S&P 500 over the initial trading days of November, filtering by those that are up more than 3 percent over the past 5 trading days. In addition to a few companies that reported strong earnings in this span like Mastercard Inc. (NYSE: MA) and The Coca-Cola Co. (NYSE: KO), this array features quite a few names traders have come to expect to lead the market. As most market watchers know, and as the chart above reveals, tech, financial and energy names took it on the chin in October, with Amazon.com, Inc. (NASDAQ: AMZN), Mastercard and Chevron Corporation (NYSE: CVX) being particularly hard hit.
- Market Realist•2 days ago
Corbus Pharmaceuticals Holdings’ Performance in 2018
Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company focused on developing and commercializing products for rare, life-threatening inflammatory fibrotic diseases.
- Zacks•2 days ago
Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer
Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.
Market Realist•2 days agoMost Analysts Are Bullish on Nektar Stock
In November 2018, of the total ten analysts covering Nektar Therapeutics (NKTR), eight analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Nektar Therapeutics stock is 1.8 with a target price of $88.5, implying an upside potential of 160.1% over Nektar Therapeutics’ trading price of $34.03 on November 10.
Market Realist•2 days agoAnalyzing Nektar Therapeutics’ Q3 Operational Performance
Nektar Therapeutics (NKTR) incurred general and administrative expenses of $18.72 million in the third quarter of 2018 as compared with $12.06 million in the third quarter of 2017. Nektar Therapeutics expects general and administrative expenses in fiscal 2018 to be higher than they were in fiscal 2017.
Market Realist•2 days agoHow Nektar Therapeutics’ Gross Margin Trended
Nektar Therapeutics’ (NKTR) non-cash royalty revenue associated with the sale of future royalties increased from $8.07 million in the third quarter of 2017 to $8.37 million in the third quarter of 2018. The significant drop in Nektar’s total revenues was attributable to a decline in license, collaboration, and other revenues, which decreased from $131.11 million in the third quarter of 2017 to $4.87 million in the third quarter of 2018.
- Business Wire•2 days ago
FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review
AstraZeneca and Merck (MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for priority review for the approval of LYNPARZA tablets as a maintenance treatment in patients with newly-diagnosed, BRCA-mutated (BRCAm) advanced ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy. A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2019.
Markit•4 days agoSee what the IHS Markit Score report has to say about Merck & Co Inc.
Merck & Co Inc NYSE:MRK
- Business Wire•4 days ago
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Hepatocellular Carcinoma (HCC) Who Have Been Previously Treated with Sorafenib
Approval Marks 14th Indication for KEYTRUDA
- Zacks•4 days ago
Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update
Catalyst (CPRX) provides pipeline update and the FDA sets action date of Nov 28, 2018 for its lead pipeline candidate, Firdapse during the third quarter of 2018.
- Zacks•4 days ago
Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag
Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.
- Business Wire•5 days ago
New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
First presentation of LENVIMA and KEYTRUDA combination data in patients with metastatic non-small cell lung cancer, metastatic melanoma and metastatic urothelial carcinoma from Stu
- Zacks•5 days ago
Merck (MRK) Gains As Market Dips: What You Should Know
Merck (MRK) closed at $75.48 in the latest trading session, marking a +0.53% move from the prior day.
- Investor's Business Daily•5 days ago
AstraZeneca Breaks Out As CEO Predicts 'Sustained Growth' Streak
AstraZeneca stock broke out Thursday after the pharma reported sales growth, claiming the quarter to be the beginning of continued growth.
- Investor's Business Daily•5 days ago
Endo Plans For Cellulite Drug In 2020 — Here's Why Investors Balked
Endo International stock crashed Thursday despite beating quarterly expectations as the generic drugmaker reportedly plans to launch its cellulite treatment in 2020.
- Zacks•6 days ago
Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise
Shares of Horizon Pharma (HZNP) rise almost 16%, owing to record quarterly sales during the third quarter of 2018.
- Investopedia•6 days ago
Merck and Johnson & Johnson Shares Show Big Buying
Gains of 13.35% and 11.09% the past three months for shares of Merck & Co., Inc. ( MRK) and Johnson & Johnson ( JNJ) tell a story of unusual bullish trading activity accompanying the moves. The main criteria we look for when betting on upside in a stock are improving fundamentals, leading technicals and bullish trading activity in the shares. Beginning in August, shares of Merck and Johnson & Johnson have increased in price alongside large increases in volume.
- Zacks•6 days ago
Democrats Hold Edge in House Battle: 5 Great Picks (Revised)
Drug and defense stocks would hugely benefit from a divided Congress.
- MarketWatch•6 days ago
Endo stock rises 6% after Q3 beats and upbeat 2018 guidance
Endo International PLC shares rose 6% in Thursday premarket trade after the company reported third-quarter adjusted profit and revenue beats and upbeat 2018 guidance. The company reported a net loss of $173.2 million, or a loss of 77 cents per share, after a loss of $96.7 million, or a loss of 43 cents per share in the year-earlier period. Endo said its adjusted earnings-per-share from continuing operations were 71 cents, above the FactSet consensus of 59 cents. Revenue declined to $745.5 million from $786.9 million in the year-earlier period, above the FactSet consensus of $694.9 million. The latest results reflect Endo's voluntary market withdrawal of the opioid pain medication Opana ER (notably, at the Food and Drug Administration's request), the company said, along with other factors like competitive pressures and discontinuations of U.S. generic drugs. Growth in the quarter, meanwhile, came from the company's launch of the antibiotic ertapenem for injection, an authorized generic for the brand-name of the antibiotic, Merck's Invanz, and continued growth in its U.S. brand-name sterile injectables products. Endo now expects 2018 revenue of $2.87 billion to $2.92 billion, above the FactSet consensus of $2.81 billion, and adjusted EPS from continuing operations of between $2.65 and $2.75, above the FactSet consensus of $2.60. Company shares have declined 1.2% over the last three months, compared with a 1.5% decline in the S&P 500 and a 2.3% rise in the Dow Jones Industrial Average .
